Cell signalling in CNS and immune system in depression and during antidepressant treatment: Focus on glial and natural killer cells

Neuroendocrinology Letters

Volumn 30, Issue 4, 2009, Pages 421-428

  Kovaru, Hana ^a   Pav, Marek ^a   Kovaru, Frantisek ^b,c   Raboch, Jiri ^a   Fiserova, Anna ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^c INSTITUTE OF ANIMAL PHYSIOLOGY AND GENETICS   (Czech Republic)

^d INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

Antidepressant; Astrocyte; cAMP; Depression; Glia; GTP binding protein; Natural killer (NK)

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; FLUOXETINE; GAMMA INTERFERON; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; IMIPRAMINE; INTERLEUKIN 1; MIANSERIN; NERVE GROWTH FACTOR; PROTEIN S100B; TUMOR NECROSIS FACTOR ALPHA;

ASTROCYTE; CELL COMMUNICATION; CELL FUNCTION; CELL POPULATION; CELL STRUCTURE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG MECHANISM; GLIA CELL; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE SYSTEM; IMMUNOREACTIVITY; INFLAMMATION; LEUKOCYTE; MAJOR DEPRESSION; NATURAL KILLER CELL; NERVE CELL PLASTICITY; NEUROANATOMY; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STRESS;

EID: 76049087655     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Althaus HH, Richter-Landsberg C (2000). Glial cells as targets and producers of neurotrophins. Int Rev Cytol. 197: 203-277.
2. Anisman H, Merali Z, Hayley S (2008). Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: Comorbidity between depression and neurodegenerative disorders. Prog Neurobiol. 85(1): 1-74.
3. Araque A, Parpura V, Sanzgiri RP, Haydon PG (1999). Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci. 22: 208-215.
4. 1A antagonists. Trends Neurosci. 19: 378-383.
5. Avissar S, Schreiber G (2006). The involvement of G proteins and regulators of receptor-G protein coupling in the pathophysiology, diagnosis and treatment of mood disorders. Clin Chim Acta. 366: 37-47.
6. Banasr M, Duman R (2008). Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviours. Biol Psychiatry. 64(10): 863-870.
7. Baorto DM, Mellado W, Shelanski ML (1992). Astrocyte process growth induction by actin breakdown. J Cell Biol. 117: 357-367.
8. Bariagaber AK, Whalen MM (2003). Decreased adenylyl cyclase and cAMP-dependent protein kinase activities inhibit cytotoxic function of human natural killer cells. Hum Immunol. 64: 866-873.
9. Chen J, Rasenick MM (1995). Chronic treatment of C6 glioma cells with antidepressant drugs increases functional coupling between a G protein (Gs) and adenylyl cyclase. J Neurochem. 64: 724-732.
10. Chung EY, Shin SY, Lee YH (2007). Amitriptyline induces early growth response -1 gene expression via ERK and JNK mitogen-activated protein kinase pathways in rat C6 glial cells. Neurosci Lett. 422: 43-48.
11. Condorelli DF, Dell'Albani P, Mudò G, Timmusk M, Belluardo N (1994). Expression of neurotrophins and their receptors in primary astroglial cultures: induction by cyclic AMP-elevating agents. J Neurochem. 63: 509-516.
12. Cooper MA, Fehniger TA, Caligiury MA (2001). The biology of human natural killer-cell subsets.Trends Immunol. 22: 633-640.
13. Cotter DR, Pariante CM, Everall IP (2001 ). Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull. 55: 585-595.
14. Coyle JT, Schwarcz R (2000). Mind glue: implications of glial cell biology for psychiatry. Arch Gen Psychiatry. 57: 90-93.
15. Donati RJ, Rasenick MM (2005). Chronic antidepressant treatment prevents accumulation of Gs alpha in cholesterol-rich, cytoskeletal-associated, plasma membrane domains (lipid rafts). Neuropsychopharmacology. 30: 1238-1245.
16. Dronjak S, Spasosjevic N, Gavrilovic L, Varagic V (2007). Effect of noradrenaline and serotonin reuptake inhibitors on pituitary-adrenocortical and sympatho-adrenomedullar system of adult rats. Neuroendocrinol Lett 28: 614-620.
17. Duman RS, Heninger GR, Nestler EJ (1997). A molecular and cellular theory of depression. Arch Gen Psychiatry. 54: 597-606.
18. Duman RS, Monteggia LM (2006). A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 59(12): 1116-1127.
19. Elmariah SB, Hughes EG, Oh EJ, Balice-Gordon RJ (2005). Neurotrophin signalling among neurons and glia during formation of tripartite synapses. Neuron Glia Biol. 1: 1 -11.
20. Engler H, Dawils L, Hoves S, Kurth S, Stevenson JR, Schauenstein K, Stefanski V (2004). Effects of social stress on blood leukocyte distribution: the role of α- and β-adrenergic mechanisms. J Neuroimmunol. 156: 153-162.
21. Evans S, Choudary CR, Neal JZ, Li MP, Vawter H,Tomita H, Lopez JF, Thomson RC, Meng F, Stead JD, Walsh SM, Myers RM, Bunney WE, Watson SJ, Jones EG, Akil H (2004). Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA. 101: 15506-15511.
22. Evans DL, Lynch KG, Benton T, Dubé B, Gettes DR, Tustin NB, Lai JP, Metzger D, Douglas SD (2007). Selective serotonin reuptake inhibitor and substance P antagonist enhancement of natural killer innate immunity in human immunodeficiency virus/acquired immunodeficiency syndrome. Biol Psychiatry. 63(9): 899-905.
23. Farina C, Aloisi F, Meinl E (2007). Astrocytes are active players in cerebral innate immunity.Trends Immunol. 28(3): 138-145.
24. Fakuda H, Nishida A, Saito H, Shimizu M, Yamawaki S (1994). Imipramine stimulates phospholipase C activity in rat brain. Neurochem Int. 25: 567-571.
25. Feinstein DL, Heneka MT, Gavrilyuk V, Dello Russo C, Wienberg G, Galea E (2002). Noradrenergic regulation of inflammatory gene expression in brain. Neurochem Int. 41: 357-365.
26. Fišerová A, Starec M, Kuldová M, Kovářů H, Páv M, Vantucci L, Pospíšil M (2002). Effects of D2-dopamine and alpha-adreno-receptor antagonists in stress induced changes on immune responsiveness of mice. J Neuroimmunol. 130: 55-65.
27. Fishman PH, Finberg JP (1987). Effect of the tricyclic antidepressant desipramine on beta-adrenergic receptors in cultured rat glioma C6 cells. J Neurochem. 49: 282-289.
28. Frank MG, Hendricks SE, Johnson DR, Wieseler JL, Burke WJ (1999). Antidepressants augment natural killer cell activity: in vivo and in vitro. Neuropsychobiology. 39: 18-24.
29. Frank MG, Hendricks SE, Burke WJ, Johnson DR (2004). Clinical response augments NK cell activity independent of treatment modality: a randomized double-blind placebo controlled antidepressant trial. Psychol Med. 34: 491-498.
30. Gavrilyuk V, Kalinin S, Hilbush BS, Middlecamp A, McGuire S, Pelligrino D, Weinberg G, Feinstein DL (2005). Identification of complement 5a-like receptor (C5L2) from astrocytes: characterization of anti-inflammatory properties. J Neurochem. 92: 1140-1149.
31. Goldman JE, Abramson B (1990). Cyclic AMP-induced shape changes of astrocytes are accompanied by rapid depolymerisation of actin. Brain Res. 528: 189-196.
32. Gubba EM, Fawcett JW, Herbert J (2004). The effects of corticosterone and dehydroepiandrosterone on neurotrophic factor mRNA expression in primary hippocampal and astrocyte cultures. Brain Res Mol Brain Res. 127(1-2): 48-59.
33. Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, Croitoru J, Brew, BJ (2001). Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 78(4): 842-853.
34. Gurguis GN, Vo SP, Griffith JM, Rush AJ (1999). Neutrophil beta(2)-adrenoceptor function in major depression: G(s) coupling, effects of Imipramine and relationship to treatment outcome. Eur J Pharmacol. 386: 135-144.
35. Haber M, Murray KK (2006). Reshaping neuron-glial communication at hippocampal synapses. In: Neuron Glia Biology 2, Cambridge University Press, pp. 59-66.
36. Haddad JJ, Saadé NE, Safieh-Garabedian B (2002). Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary- adrenal revolving axis. J Neuroimmunol. 133: 1-19.
37. Halper JP, Brown RP, Sweeny JA, Kocsis JH, Peters A, Mann JJ (1988). Blunted β-adrenergic responsivity of peripheral blood mononuclear cells in endogenous depression. Arch Gen Psychiatry 45: 241-244.
38. Hannson E, Simonsson P, Alling C (1990). Interactions between cyclic AMP and inositol phosphate transduction systems in astrocytes in primary culture. Neuropharmacology. 2: 591-598.
39. Hayley S, Poulter MO, Merali Z, Anisman H (2005). The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience. 135: 659-678.
40. Hertz L, Chen Y, Gibbs ME, Zang P, Peng L (2004). Astrocytic adrenoceptors: a major drug target in neurological and psychiatric disorders? Curr Drug Targets CNS Neurol Disord. 3: 239-267.
41. Hisaoka K, Nishida A, Koda T, Miyata M, Zensho H, Morinobu S, Ohta M, Yamawaki S (2001). Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem. 79: 25-34.
42. Hisaoka K, Takebayashi M, Tsuchioka M, Maeda N, Nakata Y, Yamawaki S (2007). Antidepressants increase glial cell line-derived neurotrophic factor production through monoamine independent activation of protein tyrosine kinase and extracellular signal-regulated kinase in glial cells. J Pharmacol Exp Ther. 321: 148-157.
43. Honegger UE, Disler B, Wiesmann UN (1986). Chronic exposure of human cells in culture to the tricyclic antidepressant desipramine reduces the number of beta-adrenoceptors. Biochem Pharmacol. 35: 1899-1902.
44. Hubbard KB, Hepler JR (2006). Cell signalling diversity of the Gqα family of heterotrimeric G proteins. Cell Signal. 18(2): 135-150.
45. Inazu M, Takeda H, Ikoshi H, Sugisawa M, Uchida Y, Matsumiya T (2001). Pharmacological characterization and visualization of the glial serotonin transporter. Neurochem Int. 39: 39-49.
46. Jetschmann JU., Benschop R., Jacobs R, Kemper A, Oberbeck R, Schmidt RE, Schedlowski M (1997). Expression and in-vivo modulation of alpha- and beta-adrenoreceptors on human natural killer (CD16+) cells. J Neuroimmunol. 74: 159-164.
47. Joniken J, Carlborg A, Mårtensson B, Forslund K, Nordström AL, Nordström P (2007). DST non-suppression predicts suicide after attempted suicide. Psychiatry Res. 150(3): 297-303.
48. Junker V, Becker A, Hühne R, Zembatov M, Ravati A, Culmsee C, Krieglstein J (2002). Stimulation of beta-adrenoceptors activates astrocytes and provides neuroprotection. Eur J Neuropharmacol. 446: 25-36.
49. Juric DM, Miklic S, Carman-Krzan M (2006). Monoaminergic neuronal activity up-regulates BDNF synthesis in cultured neonatal rat astrocytes. Brain Res. 1108: 54-62.
50. Katafuchi T, Ichijo T, Hori T (1993). Hypothalamic modulation of splenic natural killer cell activity in rats. J Physiol. 471: 209-221.
51. Kimelberg HK,Katz DM (1985). High-affinity uptake of serotonin into immunocytochemically identified astrocytes. Science 228: 889-891.
52. Kleim JA, Markham JA, Vij K, Freese JL, Ballard DH, Greenough WT (2007). Motor learning induces astrocytic hypertrophy in the cerebellar cortex. Behav Brain Res. 178: 244-249.
53. Kirwan SE, Burshtyn DN (2007). Regulation of natural killer cell activity. Curr Opin Immunol. 19(1): 46-54.
54. Kitzlerová E, Anders M (2007). The role of some new factors in the pathophysiology of depression and cardiovascular disease: Overview of recent research. Neuro Endocrinol Lett. 28(6): 832-840.
55. Koe BK, Lebel LA (1995). Effects of serotoninergic agents on down regulation of beta-adrenoceptors by the selective serotonin reuptake inhibitor sertraline. Arch Int Pharmacodyn Ther. 329: 231-244.
56. Koo JW, Duman RS (2008). IL-1 beta is an essential mediator oft he antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA. 105(2): 751-756.
57. Kovářů H, Fišerová A, Lisá V, Španová A, Kovářů F, Velek J (1997). Fluoxetine induced changes in C6 glioma cells and NK lymphocytes. In: Biologické základy psychických poruch. (Eds. J.Sikora, Z.Fišar et al.), Galén Publ Co, Praha: pp. 108-112.
58. Kovářů H, Fišerová A, Kovářů F, Paclt I, Lisá V (2000). Antidepressant or immunomodulator induced regulation of cell signalling in brain and immune system. Eur. Neuropsychopharmacol. 10, Suppl 3:269-270.
59. Kovářů H, Fišerová A, Kovářů F, Pospíšil M, Lisá V (2001). Modulation of heterotrimeric GTP-binding proteins in immune system and brain. Czech J Anim Sci. 46:62-67.
60. Kovářů H, Kovářů F (2005). Basis of neuroimmunomodulation. In: Základy neuroimunomodulace, Galén, Praha: pp. 203-208.
61. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF (2002). Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 7(Suppl 1): S71-S80.
62. Kubera M, Basta-Kaim A, Skowron-Cendrzak A, Mazur-Kolecka B, Roman A, Boryc, J (1995). Effect of repeated amitriptyline administration to mice on the T lymphocyte proliferative activity and natural killer cell cytotoxicity. Pol J Pharmacol. 47: 321-326.
63. Leavitt M, Setola V, Fishman PH (2001). Protein kinase C-mediated down-regulation of beta(2)-adrenergic receptor and gene expression in rat C6 glioma cells. J Neurochem. 77:823-829.
64. Ledeboer A, Brevé JJ, Poole S, Tilders FJ, Van Dam AM (2000). lnterleukine-10, interleukine-4, and transforming growth factor-beta differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. Glia 30: 134-142.
65. Lee HJ, Cha JH, Ham BJ, Han CS, Kim YK, Lee SH, Ryu SH, Kang RH, Choi MJ, Lee MS (2004). Association between G-protein beta3 subunit gene polymorphism and the symptomatology and treatment responses of major depressive disorders. Pharmacogenomics. 4:29-33.
66. Lee Y, Gaskins D, Anand A, Shekkar A (2007). Glia mechanisms in mood regulation: a novel model of mood disorders. Psychopharmacology (Berl). 191:55-65.
67. Leonard BE (2001). The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry. 25:767-780.
68. Lesch KP, Hough CJ, Aulakh CS, Wolozin BL, Tolliver TJ, Hill JL, AkioyoshiJ, Chuang DM, Murphy DL (1992). Fluoxetine modulates G protein alpha s, alpha q, and alpha 12 subunit mRNA expression in rat brain. Eur J Pharmacol. 277:233-237.
69. Li Z, Vaidya VA, Alvaro JD, lredale PA, Hzu R, Hoffmann G, Fidzgerald L, Curran PK, Machida CA, Fishmann PH, Duman RS (1998). Protein kinase C mediated down-regulation of À1-adrenergic receptor gene expression in rat C6 glioma cells. Mol Pharmacol. 54:14-21.
70. Luttrell LM (2006). Transmembrane signalling by G protein-coupled receptors. Methods Mol Biol. 332:3-49.
71. Maes M (2001). The immunoregulatory effect of antidepressants. Hum Psychopharmacol. 16:95-103.
72. Maes M, Mihaylova I, Ruyter MD, Kubera M, Bosmans E (2007). The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation. Neuroendocrinol Lett. 28(6): 826-831.
73. Maes M (2008). The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuroendocrinol Lett. 29(3): 287-291.
74. Mann JJ, Mahler JC, Wilner PJ, Halper JP, Brown RP, Johnson KS, Kocsis JH, Chen J (1990). Normalisation of blunted lymphocyte β-adrenergic responsivity in melancholic inpatients by a course of electroconvulsive therapy. Arch Gen Psychiatry. 47:461-464.
75. Mann JJ, Halper JP, Wilner PJ, Sweeny JA, Mieczkowski TA, Chen JS, Stokes PE, Brown RP (1997). Subsensitivity of adenylyl cyclase-coupled receptors on mononuclear leukocytes from drug-free inpatients with a major depressive episode. Biol Psychiatry. 42:859-870.
76. Manev R, Uz T, Manev H (2001 ). Fluoxetine increases the content of neurotrophic protein S1OObeta in the rat hippocampus. Eur J Pharmacol. 420:1-2.
77. Manev H, Uz T, Manev R (2003). Glia as a putative target for antidepressant treatments. J Affect Disord. 75:59-64.
78. Matalka KZ (2003). Neuroendocrine and cytokines-induced responses to minutes, hours and days of mental stress. Neuroendocrinol Lett. 24:283-292.
79. Matuzany-Ruban A, Avissar S, Schreiber G (2005). Dynamics of beta-arrestin1 protein and mRNA levels elevation by antidepressants in mononuclear leukocytes of patients with depression. J Affect Disord. 88:307-312.
80. Mendlewicz J, Hubain PP, Koumakis C (1984). Further investigation of the dexamethasone suppression test in affective illnesses: relationship to clinical diagnosis and therapeutic response. Neuropsychobiology. 12(1): 23-26.
81. Menkes DB, Rasenick MM, Wheeler MA, Bitensky MW (1983). Guanosine triphosphate activation of brain adenylate cyclase: enhancement by long-term antidepressant treatment. Science 219:65-67.
82. Mercier G, Lennon AM, Renouf B, Dessouroux A, Ramaugé M, Courtin F, Pierre M (2004). MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes. J Mol Neurosci. 24:207-216.
83. Miklic S, Juric DM, Carman-Krzan M (2004). Differences in the regulation of BDNF and NGF synthesis in cultured neonatal rat astrocytes. Int J Dev Neurosci. 22:119-130.
84. Mourlevat S, Troadec JD, Ruberg M, Michel PP (2003). Prevention of dopaminergic neuronal death by cyclic AMP in mixed neuronal/glial mesencephalic cultures requires the repression of presumptive astrocytes. Mol Pharmacol. 64:578-586.
85. Müller N, Schwartz MJ (2007). The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry. 12:988-1000.
86. Nair A, Vaidya VA (2006). Cyclic AMP response element binding protein and brain-derived neurotrophic factor: molecules that modulate our mood? J Biosci. 31:423-434.
87. Nelson DR, Palmer KJ, Johnson AM (1990). Effect of prolonged 5-hydroxytryptamine uptake inhibition by paroxetine on cortical beta 1- and beta 2-adrenoceptors in rat brain. Life Sci. 47: 1683-1691.
88. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002). Neurobiology of depression. Neuron. 34:13-25.
89. Niu H, Hinkle DA, Wise PM (1997). Dexamethasone regulates basic fibroblast growth factor, nerve growth factor and S1OObeta expression in cultured hippocampal astrocytes. Brain Res Mol Brain Res. 51:97-105.
90. Normann C, Schmitz D., Fũrmaier A, Doing C, Bach M (2007). Long-term plasticity of visually evoked potentials in humans is altered in major depression. Biol Psychiatry. 62(5): 373-380.
91. Orange JS, Ballas ZK (2006). Natural killer cells in human health and disease. Clin Immunol. 118(1): 1-10.
92. Páv M, Kovářů H, Fišerová A, Havrdová E, Lisá V. (2008) Neurobiological aspects of depressive disorder and antidepressant treatment: role of glia. Physiol Res. 57(2): 151-164.
93. Parpura V, Haydon PG (2000). Physiological astrocytic calcium levels stimulate glutamate release to modulate adjacent neurons. Proc Natl Acad Sci USA. 97:8196-8234.
94. Paul IA, Skolnick P (2003). Glutamate and depression: clinical and preclinical studies. Ann N Y Acad Sci. 1003:250-272.
95. Pellegrino TC, Bayer BM (1998). Modulation of immune cell function following fluoxetine administration in rats. Pharmacol Bichem Behav. 59:151-157.
96. Perea G, Araque A (2005a). Properties of synaptically evoked astrocyte calcium signal reveal synaptic information processing by astrocytes. J Neurosci. 25:2192-2203.
97. Perea G, Araque A (2005b). Glial calcium signalling and neuronglia communication. Cell Calcium. 38:375-382.
98. Perea G, Araque A. (2007) Astrocytes potentiate transmitter release at single hippocampal synapses. Science. 317: 1083-1086.
99. Procopio AD, Paolini R, Gismondi A, Picolli M, Cavallo G, Frati L, Santoni A (1989). Effects of protein kinase C (PK-C) activators and inhibitors on human large granular lymphocytes (LGL): role of PK-C on natural killer (NK) activity. Cell Immunol. 118: 470-481.
100. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholzer JC, Roth BL, Stockmeier CA (1999). Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 45:1085-1098.
101. Rajkowska G, Miguel-Hidalgo JJ (2007). Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 6: 219-233.
102. Reynaert, anne P, Body A, Staquet P., Zdanowicz N, Vause M, Chatelein B (1995): From health focus of control to immune control: internal locus has a buffering effect on natural killer cell activity decrease in major depression. Acta Psychiat Scand. 92: 294-300.
103. Ridet JL, Malhotra SK, Privat A, Gage FH (1997). Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 20(12): 570-577.
104. Sadock BJ, Sadock VA (2005). Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Eight Edition. Lippikott Williams & Wilkins.Vol.l, pp. 1559-1718.
105. Saito M, Hori M, Obara Y, Ohizumi Y, Ohkubo S, Nakahata N (2006). Neurotrophic factor production in human astrocytoma cells by 2,5,6-tribromogramine via activation of epsilon isoform of protein kinase C. Eur J Pharm Sci. 28:263-271.
106. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas Gl, Pollack MH, Nierenberg AA, Fava M, Wong KK (2007). A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol. 18:230-233.
107. Sofroniew MV (2005). Reactive astrocytes in neural repair and protection. Neuroscientist. 11:40-47.
108. Spiegel AM (1996). Defects in G protein-coupled signal transduction in human disease. Ann Res Physiol.58:143-170.
109. Steel JL, Geller DA, GamblinTC, Olek MC, Carr BI (2007). Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol. 25:2397-2405.
110. Steele TA, Brahmi Z (1988). Phosphatidylinositol metabolism accompanies early activation events in tumor target cell-stimulated human natural killer cells. Cell Immunol. 112:402-413.
111. Tiraboshi E, Tardito D, Kasahara J, Morashi S, Pruneri P, Gennarelli M, Racagni G, Popoli M (2004). Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades. Neuropsychopharmacology. 29: 1831-1840.
112. Torgersen KM, Vaage JT, Levy FO, Hansson V, Rolstad B, Tasken K (1997). Selective activation of cAMP-dependent protein kinase type I inhibits rat natural killer cell cytotoxicity. J Biol Chem. 272:5495-5500.
113. Trzonkowski P, Mysliwska J, Godlewska B, Szmit E, Lukaszuk K, Wieckiewicz J, Brydak L, Machala M, Landowski J, Mysliwski A (2004). Immune consequences of the spontaneous proinflammatory status in depressed elderly patients. Brain Behav Immun. 18(2): 135-148.
114. Watson S, Gallagher P, Smith MS, Ferrier IN, Young AH (2006). The dex/CRH test - is it better than the DST? Psychoeuroendocrinology. 31(7): 889-894.
115. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HC, Joyce PR, Karam EG, Lee CK, Lellouch J, Lépine JP, Newman SC, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen H, Yeh EK (1996). Cross-national epidemiology of major depression and bipolar disorder. JAMA 276(4): 293-299.
116. Wettschureck N, Offermanns S (2005). Mammalian G proteins and their cell type specific functions. Physiol Rev. 85(4): 1159-1204.
117. Whalen MM, Bankhurst AD (1990). Effects of β-adrenergic receptor activation, cholera toxin and forskolin on human natural killer cell function. Biochem J. 272:327-331.
118. Won CL, Oh IS (2000). cAMP- induced stellation in primary astrocyte cultures with regional heterogeneity. Brain Res. 887: 250-258.
119. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R, Seligman DA, Schmidt K (2001). The relationship of depression and stressors to immunological assays: A metaanalytic review. Brain Behav Immun. 15:199-226.